The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer
Yükleniyor...
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Wolters Kluwer Medknow Publications
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Background: Studies on single nucleotide polymorphisms (SNPs) in non‑small cell lung cancer (NSCLC) suggest that DNA repair
capacity may have prognostic implications for disease recurrence and survival. However, there is no study investigating the relationship
between SNPs and the risk of metastasis at the time of initial diagnosis in patients with NSCLC.
Objective: This study aimed to investigate the potential predictive value of SNPs in detecting the risk of metastasis at the time of
initial diagnosis and poor prognosis in patients with NSCLC.
Material and Methods: In this prospective cohort study, we evaluated 275 patients with NSCLC. Analysis of SNPs from peripheral
blood cells was performed by a polymerase chain reaction. Excision repair cross‑complementing group 1 (ERCC1)‑ Asn118Asn,
excision repair cross‑complementing group 2 (ERCC2)‑Lys751Gln, X‑ray repair cross‑complementing group 1 (XRCC1)‑Arg399Gln,
and tumor protein 53 (TP53)‑Arg72Pro polymorphisms were evaluated in conjunction with the development of metastasis.
Results: The ERCC1 normal genotype, ERCC2 heterozygote genotype, XRCC1 normal genotype, and TP53 normal genotype were
associated with a higher stage and more advanced‑stage disease at the time of initial diagnosis (P = 0.027, 0.005, <0.001, and
0.006, respectively). Also, XRCC1 normal genotype and TP53 normal genotype were associated with the risk of metastasis at the
time of initial diagnosis (P = <0.001 and 0.002, respectively). Moreover, the XRCC1 normal genotype was associated with the risk
of brain metastasis at the time of initial diagnosis (P = 0.031).
Conclusions: We showed that SNPs are related to a higher stage and more advanced‑stage disease at the time of initial diagnosis
in patients with NSCLC, and XRCC1 and TP53 gene polymorphisms are associated with the risk of metastasis. These results may
contribute to the identification of high‑risk groups and may help to earlier diagnosis and treatment in patients with NSCLC.
Açıklama
Anahtar Kelimeler
Biomarker, Metastasis, Non-small cell lung cancer, Single nucleotide polymorphism, Stage
Kaynak
Journal of Cancer Research and Therapeutics
WoS Q Değeri
N/A
Scopus Q Değeri
Q3
Cilt
19
Sayı
5
Künye
Karaağaç, M., Geredeli, Ç., Yıldırım, M. S., Altınok, T., Dede, İ., İnal, A. ve diğerleri. (2023). The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer. Journal of Cancer Research and Therapeutics, 19(5), 1248-1254.
